

DORMANT

Registration number: 11335096

# Mid Essex Newmedica Limited

Annual Report and Unaudited Financial Statements

for the Period from 28 April 2018 to 28 February 2019



## **Mid Essex Newmedica Limited**

### **Contents**

Company information	1
Balance Sheet	2
Notes to the Financial Statements	3 to 5

## **Mid Essex Newmedica Limited**

### **Company information**

**Directors** New Medical Systems Limited  
Darshak Ashok Shah  
Giles Stuart Rutherford Edmonds

**Company secretary** New Medical Systems Limited

**Registered office** Castleworks  
21 St George's Road  
London  
England  
SE1 6ES

**Registration number** 11335096

**Mid Essex Newmedica Limited**  
**(Registration number: 11335096)**  
**Balance Sheet as at 28 February 2019**

	Note	2019 £
<b>Current assets</b>		
Debtors	3	<u>1</u>
<b>Capital and reserves</b>		
Called up share capital	4	<u>1</u>
Total equity		<u>1</u>

For the financial period ending 28 February 2019 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.


**Directors' responsibilities:**

- The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

25/3/2019 | 12:46 GMT

Approved and authorised by the Board on ..... and signed on its behalf by:

DocuSigned by:  
  
 .....  
 Director  
 Giles Edmonds

## Mid Essex Newmedica Limited

### Notes to the Financial Statements for the Period from 28 April 2018 to 28 February 2019

#### 1 General information

The company is a private company limited by share capital incorporated in the United Kingdom.

The address of its registered office is:

Castleworks  
21 St George's Road  
London  
England  
SE1 6ES

#### 2 Accounting policies

##### Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value. The directors have included the balances owed to and from Specsavers Finance (Guernsey) Limited, the Group Treasury Company within cash equivalents. If the overall cash balance with the Group Treasury Company is overdrawn, this is classified as a current liability alongside any other overdrawn external cash balances.

##### Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

##### Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

#### 3 Debtors

	2019 £
Other debtors	1
Total trade and other debtors	1

#### 4 Share capital

Allotted, called up and fully paid shares

**Mid Essex Newmedica Limited**

**Notes to the Financial Statements for the Period from 28 April 2018 to 28 February 2019**

**4 Share capital (continued)**

	<b>28 February 2019</b>	
	<b>No.</b>	<b>£</b>
"A" Ordinary of £0.50 each	-	-
"B" Ordinary of £0.50 each	1	1
	<u>1</u>	<u>1</u>
	<u>1</u>	<u>1</u>

## **Mid Essex Newmedica Limited**

### **Notes to the Financial Statements for the Period from 28 April 2018 to 28 February 2019**

#### **4 Share capital (continued)**

##### **Rights, preferences and restrictions**

In accordance with the Articles of Association the following rights attach to shares: a) to "A" shares, the right to receive that part (including the whole) of the profits of the company which the directors shall, from time to time, determine to distribute as dividends. b) to "B" shares, the right to appoint the chairman of the board of directors and of the general meeting of the company. The "B" shares are held by New Medical Systems Limited. In all other respects both classes of share carry equal rights over the assets of the company, subject to those provisions as laid out in the shareholders' agreement.

#### **5 Parent and ultimate parent undertaking**

As at the year end Specsavers International Healthcare Limited was the ultimate parent company of Mid Essex Newmedica Limited. Mr and Mrs Perkins have the controlling interest in the ordinary share capital of Specsavers International Healthcare Limited, the ultimate parent company. Specsavers International Healthcare Limited is a Guernsey registered company and its accounts are not available to the public.

Specsavers Eye Care Services Limited is the parent company of the smallest group for which consolidated financial statements are drawn up and in which Mid Essex Newmedica Limited is a member. Specsavers Eye Care Services Limited registered office is:

Forum 6  
Parkway  
Solent Business Park  
Whiteley  
Fareham  
Hampshire  
PO15 7PA

#### **6 Non adjusting events after the financial period**

If dividends were paid after the year ended 28 February 2019, which will be accounted for in the shareholders' equity as an appropriation of retained earnings in the year ended 29 February 2020, the financial statements do not reflect these. The company has controls in place to ensure that there are sufficient retained earnings to cover dividend payments based on the latest available management information at the dividend declaration date so that the company remains in a net asset position.

The cost of disclosing and repeatedly updating the quantum of these dividends, right up to the date of signing the financial statements, is therefore considered to exceed any benefit to the users thereof.